BCM
VRCA icon

BML Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

BML Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,465
Closed -$92.6K – 28
2025
Q2 		$92.6K Hold
17,465
– – 0.07% 24
2025
Q1 		$77.2K Hold
17,465
– – 0.06% 25
2024
Q4 		$122K Sell
17,465
-535
-3% -$5.88K 0.08% 23
2024
Q3 		$261K Hold
18,000
– – 0.15% 28
2024
Q2 		$1.31M Hold
18,000
– – 0.94% 18
2024
Q1 		$1.07M Hold
18,000
– – 0.7% 23
2023
Q4 		$1.32M Buy
18,000
+3,000
+20% +$123K 1% 19
2023
Q3 		$583K Hold
15,000
– – 0.54% 18
2023
Q2 		$866K Hold
15,000
– – 0.78% 20
2023
Q1 		$975K Sell
15,000
-96,061
-86% -$5.81M 0.84% 23
2022
Q4 		$3.05M Buy
+111,061
New +$2.96M 2.92% 11

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

BML Capital Management's VRCA Position: Q3 2025 in Review

BML Capital Management sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 17,465 shares — an estimated $92.6K sold.

BML Capital Management first reported a position in VRCA in Q4 2022 and held it in 11 quarters. The position peaked at $3.05M in Q4 2022. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • BML Capital Management reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • BML Capital Management sold 17,465 Verrica Pharmaceuticals shares in Q3 2025, an estimated $92.6K.
  • BML Capital Management first reported a position in Verrica Pharmaceuticals in Q4 2022 and held it in 11 quarters.
  • BML Capital Management's Verrica Pharmaceuticals position peaked at $3.05M in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on BML Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.